Our portfolio
Anacor

Novel small-molecule therapeutics development leverages boron chemistry

Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation’s investment helps support the development of preclinical drug candidates.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Public
  • Partnered in
    2013
  • Investment lead
    David Rossow
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences
Portfolio news
In 2016, Anacor was acquired by Pfizer

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.